The Utility of Afatinib in Lung Cancer

Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses the utility of afatinib in patients with lung cancer.

Clinical Pearls

Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses the utility of afatinib in patients with lung cancer.

  • Results from the LUX-Lung 3 trial demonstrated benefit with afatinib compared with cisplatin/pemetrexed in patients with advanced lung adenocarcinoma withEGFRmutations
  • Afatinib is now available in the U.S.
  • How afatinib compares with other TKIs is still up for debate